Australia ‘unlikely’ to see recession: Maple-Brown Abbott
Interest rate cycles do not guarantee the doom and gloom of current economic forecasts, according to a boutique fund manager, and markets could see outperformance.
Dougal Maple-Brown, head of Australian value equities at Maple-Brown Abbott, challenged the growing expectation that the nation would enter a recession in 2023.
Current interest rates presented similarities to the economic conditions of 1994, where interest rates grew by 2.75% over a five-month span.
“The economy didn't go backwards in 1994. Markets admittedly did. But the rate cycle is not unprecedented, and it doesn't guarantee a recession.
“The fall in global equity markets so far has largely been caused by a price-to-earnings (P/E) de-rating. Effectively, interest rates have gone up, market multiples have come down but earnings have not moved very much at all in most markets,” he commented.
In relation to the Reserve Bank of Australia (RBA) tightening monetary policy, Maple-Brown said: “Everyone keeps saying it's unprecedented, but it's actually not.”
Reflecting on Australia’s economic history could be beneficial when knowing what to expect during a bear market, he identified.
Maple-Brown added that market P/E averages were often deceiving and obscured wide dispersion between sectors.
The Australian market was trading at a forward price-to-earnings ratio of approximately 13-14 times, about 10% below the long-term average.
Furthermore, separating the higher-performing sectors from those trading on lower multiples provided a more accurate depiction of the investor climate.
“Market conditions should continue to support value managers who can seek out the best performers in the right sectors. We are optimistic there is further outperformance to come,” Maple-Brown said.
AUTHOR
Jasmine Siljic
Recommended for you
Global X has painted a worrying picture for active ETFs in Australia, with investor adoption proving uneven and the popularity of its low-cost index counterparts only growing stronger.
Australian equity ETFs attracted record inflows of $3.2 billion in 1Q25, while heightened volatility led to a decline in flows for global equity ETFs, according to Vanguard.
The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under management, quarterly flows show.
GQG Partners has revealed its quarterly flows for the first three months of 2025 were up 5.8 per cent, after a difficult final quarter of 2024 as a result of institutional redemptions.
